Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations will be less than £5 million per year in England (or £9,000 per 100,000 population).
The technology is a further treatment option and due to this the overall incremental cost of treatment is not deemed to be significant.
The addition of avatrombopag in the treatment pathway may help reduce the need for platelet transfusions. It may also help increase the time in which procedures can be scheduled and reduce hospital stays.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: